Multaq (dronedarone) most commonly causes digestive problems, particularly diarrhea, nausea, abdominal pain, and vomiting. But it also carries serious risks, including a boxed FDA warning about increased death in patients with severe heart failure. Understanding both the everyday side effects and the rare but dangerous ones can help you know what to watch for while taking this medication.
Multaq is prescribed to maintain a normal heart rhythm in people with atrial fibrillation or atrial flutter. It’s chemically related to an older drug called amiodarone but was designed without iodine in its structure, specifically to reduce the thyroid, lung, and eye toxicity that amiodarone is known for. That design choice succeeded in some ways but didn’t eliminate all organ risks.
Common Side Effects
The most frequent side effects are gastrointestinal. Diarrhea is the one patients report most often, followed by nausea, abdominal pain, and vomiting. These tend to appear early in treatment and are usually manageable, but they can be persistent enough that some people stop taking the drug.
Other relatively common effects include general weakness, fatigue, and skin reactions like rashes. Some patients notice a slow heart rate (bradycardia), especially if they’re also taking beta-blockers or certain blood pressure medications. Your prescriber will typically start those other medications at lower doses and check your heart rhythm before increasing them.
The Heart Failure Warning
Multaq carries the FDA’s most serious label warning: a black box warning about heart failure. In a clinical trial called ANDROMEDA, patients with severe heart failure who took Multaq had more than double the death rate compared to those on a placebo. Because of this, Multaq is contraindicated in people with the most severe class of heart failure (NYHA Class IV) and in those with moderate heart failure that recently worsened enough to require hospitalization or a referral to a heart failure specialist.
This is not a theoretical risk. If you have any history of heart failure, your doctor needs to know before you start Multaq, and you should be aware of new or worsening symptoms like shortness of breath, swelling in the legs, or sudden weight gain while on the medication.
Liver Injury
Multaq has been linked to rare but serious liver damage, including cases of acute liver failure. In one published case, a 70-year-old woman developed progressive fatigue and jaundice over two weeks. Her condition deteriorated rapidly, with signs of liver failure including confusion from a buildup of toxins the liver could no longer clear. Liver biopsy showed widespread tissue death and severe bile buildup.
Because of reports like this, the FDA recommends liver function testing before starting Multaq and periodically during treatment. Signs of liver trouble to watch for include unusual fatigue, loss of appetite, nausea, dark urine, or yellowing of the skin or eyes. If any of these develop, blood work to check liver function should happen promptly.
Lung Problems
Although Multaq was engineered without iodine partly to avoid the lung scarring associated with amiodarone, cases of lung inflammation and fibrosis have still been reported. The risk appears to be higher in patients over 65, particularly those who previously took amiodarone. In fact, Multaq should not be used as a substitute for amiodarone in patients who already developed lung toxicity from that drug.
Monitoring lung function before and during treatment is recommended, especially for people with prior amiodarone exposure. Symptoms to be aware of include a new or worsening cough, shortness of breath, or difficulty breathing during exertion. If lung function declines, the drug should be stopped.
How Multaq Interacts With Other Drugs
Multaq has a long list of drug interactions, some of which are dangerous enough to be outright contraindicated. The drug is broken down by a specific enzyme system in the liver, and anything that strongly blocks that system can cause Multaq levels to spike. Contraindicated drugs include certain antifungals (ketoconazole, itraconazole, voriconazole), the antibiotic clarithromycin, the antidepressant nefazodone, the immunosuppressant cyclosporine, and the HIV drug ritonavir.
Grapefruit juice is a notable interaction many people don’t expect. It tripled the amount of Multaq absorbed into the bloodstream in studies, so you should avoid grapefruit juice entirely while on this medication.
Other heart rhythm drugs (both Class I and Class III antiarrhythmics, including amiodarone, sotalol, and flecainide) must be stopped before starting Multaq. Combining them risks dangerous heart rhythm disturbances.
Several common medications require dose adjustments:
- Digoxin: Multaq raises digoxin levels in the blood, so the digoxin dose typically needs to be cut in half, with closer monitoring for toxicity.
- Statins: Multaq can increase the blood levels of certain cholesterol-lowering drugs significantly. Simvastatin exposure, for example, roughly quadrupled in studies.
- Blood thinners: Multaq slightly increases exposure to one component of warfarin. Clinical trials didn’t show excess bleeding, but regular monitoring of clotting levels is still recommended.
- Beta-blockers and calcium channel blockers: Both can amplify Multaq’s tendency to slow the heart rate. Starting at low doses with heart rhythm monitoring before increasing is the standard approach.
Herbal products matter too. St. John’s wort significantly reduces Multaq’s effectiveness by speeding up how fast the body breaks it down, so the combination should be avoided.
Why It Must Be Taken With Food
Multaq is taken as one 400 mg tablet with breakfast and one with dinner. This isn’t optional guidance. Without food, only about 4% of the drug actually reaches your bloodstream. Taken with a meal, that number rises to around 15%. Skipping meals or taking it on an empty stomach means the drug may not work as intended.
How It Compares to Amiodarone
Many people prescribed Multaq are already familiar with amiodarone, the older drug it was modeled after. Multaq was specifically designed to avoid amiodarone’s most troublesome long-term side effects. Removing the iodine from the molecule eliminated the thyroid problems that affect a significant portion of amiodarone users. Animal studies confirmed that Multaq does not alter circulating thyroid hormone levels. The chemical modification also reduced the drug’s tendency to accumulate in fatty tissue, which is what causes amiodarone’s slow, months-long clearance from the body.
That said, Multaq is generally considered less potent at controlling heart rhythm than amiodarone. The trade-off is a cleaner side effect profile for most patients, with the important exceptions of the heart failure risk and the rare but real possibility of liver and lung injury. It’s a different balance of risks, not a risk-free alternative.